We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...
The green light from the FDA puts further pressure on Biogen, currently grappling with weaker sales of its MS products, pipeline setbacks, and misfired launches that have forced it to slash staff ...
The patents cover sales of Biogen products for MS that are covered by a Forward Pharma patent and have dimethyl fumarate as an active pharmaceutical ingredient. The two companies say they intend ...
Happy to be moderating my annual panel where Priya has to listen to me pepper her with questions for 40 minutes or so with Priya Singhal, Head of Development at Biogen. Thank you, Priya for ...
Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority ...
"The global industry was valued at US$ 37.0 Bn in 2023 and is projected to reach US$ 64.8 Bn by 2034, growing at a CAGR of ...
VJ received conference travel support from Merck and Roche and speaker’s honoraria from Biogen and Roche outside of the submitted work. She receives research support from the Australian National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback